Skip to content
Screener

Alkermes ALKS Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$392.9MBeat by $29.9M
EPS-$0.40Beat by $0.17
Revenue estimate$363.1M
EPS estimate-$0.57

Next report

Oct 28, 2026 (in a month)
Revenue estimate$463.9M
EPS estimate-$0.08

Financials

Q1 2026

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$5.89B+9.7%
Enterprise value$7.12B+41.2%
P/E38.6×+23.4×
P/S3.8×+0.2×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Segments

By product

See full
Vivitrol$112.4M—
Aristada And Aristada Initio$93.8M—
LYBALVI$92.4M—
LUMRYZ$39.5M—

FAQ

When did Alkermes report Q1 2026 earnings?
Alkermes (ALKS) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Alkermes's Q1 2026 revenue and EPS?
Alkermes reported revenue of $392.9M and eps of $-0.40 for Q1 2026.
Did Alkermes beat estimates in Q1 2026?
Revenue beat the consensus estimate of $363.1M by $29.9M. EPS beat the consensus estimate of $-0.57 by $0.17.
How did Alkermes's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 28.2% from $306.5M a year earlier.
Where can I find Alkermes's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-205008) and the 10-Q periodic report (0001193125-26-206534) directly on SEC EDGAR. The filing index links above go to sec.gov.